RPG Life Sciences Ltd

• Investor presentation released for Q4 and FY26 results. • Company highlights consistent market outperformance. • Focus on core brand growth, specialty portfolio, and global expansion. • Emphasis on cost efficiency, quality, and R&D innovation.

📊 Quarterly & Annual Financial Results Update

The company released its investor presentation for Q4 and FY26 results, offering a detailed view of performance and plans.

🔍 Overview:

• Presentation covers Q4 (ending March 31, 2026) and full fiscal year results.
• Designed to provide insights into business performance and strategy.

📈 Market Performance:

• Consistent outperformance versus Indian Pharmaceutical Market (IPM) in all FY26 quarters.
• Domestic formulations grew 1.6 to 1.8 times faster than IPM.
• Improved IPM ranking from 58th to 52nd, showing growing presence.

💼 Business Focus Areas:

1. Brand Growth: Focus on scaling core brands with double-digit growth, targeting ₹100 crore+ brands.
2. Specialty Portfolio: Expanding chronic and specialty therapies with new launches.
3. API Business: Strengthening active pharmaceutical ingredients segment post disruptions.
4. Global Expansion: Investing to increase global footprint and customer engagement.
5. Cost & ESG: Cost discipline and ESG practices for sustainable operations.

🏭 Operational Improvements:

• Enhancing manufacturing capacity for scalable growth.
• Cost optimization and productivity improvements to enhance margins.
• Strengthening quality standards for consistent reliability.

🔬 Innovation & Digital Adoption:

• Heavy investment in R&D for new product launches and specialty expansion.
• Using digital tools to improve operational execution and productivity.

📊 Product & Market Details:

• Mainly domestic formulations (65%+ of sales) and synthetic API segments.
• Focus on therapies like immunosuppressants, oncology, neuropsychiatry, etc.

🎯 Summary:

The presentation highlights strong market performance, growth strategy, operational and innovation focus, and plans for expansion providing investors useful insight about the company’s trajectory. Quantitative financial details are limited to growth multiples and market rank improvements in this summary.